{"generic":"Irbesartan","drugs":["Avapro","Irbesartan"],"mono":{"0":{"id":"924382-s-0","title":"Generic Names","mono":"Irbesartan"},"1":{"id":"924382-s-1","title":"Dosing and Indications","sub":{"0":{"id":"924382-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Diabetic nephropathy:<\/b> target maintenance dose, 300 mg ORALLY once daily<\/li><li><b>Hypertension:<\/b> 150 mg ORALLY once daily; may titrate to MAX of 300 mg once daily<\/li><\/ul>"},"2":{"id":"924382-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>volume- or salt-depleted patients:<\/b> start with 75 mg orally once daily<\/li><li><b>hemodialysis:<\/b> start with 75 mg orally once daily<\/li><\/ul>"},"3":{"id":"924382-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Diabetic nephropathy<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Hypertension - Renal impairment<\/li><li>Left ventricular hypertrophy<\/li><li>Recurrent atrial fibrillation; Prophylaxis<\/li><li>Renal impairment, chronic<\/li><\/ul>"}}},"2":{"id":"924382-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>When pregnancy is detected, discontinue irbesartan as soon as possible; drugs that act directly on the renin-angiotensin system can cause serious fetal toxicity.<br\/>"},"3":{"id":"924382-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924382-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant aliskiren use in diabetic patients<\/li><li>hypersensitivity to irbesartan or to any component of the product<\/li><\/ul>"},{"id":"924382-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- avoid use during second and third trimester of pregnancy; drug may cause fetal and neonatal morbidity and death; discontinue therapy as soon as possible when pregnancy is detected<\/li><li>Cardiovascular:<\/li><li>-- symptomatic hypotension may occur with high dose diuretic therapy or increased diuretic doses, heart failure, hyponatremia, renal dialysis, or severe volume or salt depletion; monitoring recommended; dose adjustment may be required<\/li><li>Renal:<\/li><li>patients whose renal function depend on the renin-angiotensin-aldosterone system, therapy may increase risk of oliguria, progressive azotemia, or acute renal failure or death<\/li><li>-- increases in serum creatinine and BUN have been reported in patients with bilateral or unilateral renal artery stenosis have been reported with ACE inhibitor use<\/li><li>Concomitant use:<\/li><li>-- concomitant use with other agents that affect the renin-angiotensin system (ie, ACE inhibitors, angiotensin receptor blockers, or aliskiren) may increase the risk of hypotension, hyperkalemia, and adverse renal function changes; monitoring recommended if coadministration is necessary<\/li><li>-- concomitant aliskiren use in renally impaired patients (ie, GFR less than 60 mL\/min) not recommended<\/li><\/ul>"},{"id":"924382-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"924382-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924382-s-4","title":"Drug Interactions","sub":[{"id":"924382-s-4-13","title":"Contraindicated","mono":"<ul>Aliskiren (probable)<\/ul>"},{"id":"924382-s-4-14","title":"Major","mono":"<ul><li>Benazepril (established)<\/li><li>Captopril (established)<\/li><li>Ceritinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Entacapone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosinopril (established)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Moexipril (established)<\/li><li>Nitisinone (theoretical)<\/li><li>Perindopril (established)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Trandolapril (established)<\/li><li>Trimethoprim (theoretical)<\/li><\/ul>"},{"id":"924382-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}]},"5":{"id":"924382-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea, Heartburn<\/li><li><b>Neurologic:<\/b>Headache<\/li><li><b>Respiratory:<\/b>Upper respiratory infection<\/li><li><b>Other:<\/b>Fatigue<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thrombocytopenia<\/li><li><b>Hepatic:<\/b>Cholestasis, Hepatitis<\/li><li><b>Musculoskeletal:<\/b>Rhabdomyolysis<\/li><li><b>Renal:<\/b>Renal failure<\/li><li><b>Other:<\/b>Angioedema, face, lips, throat<\/li><\/ul>"},"6":{"id":"924382-s-6","title":"Drug Name Info","sub":{"0":{"id":"924382-s-6-17","title":"US Trade Names","mono":"Avapro<br\/>"},"2":{"id":"924382-s-6-19","title":"Class","mono":"<ul><li>Angiotensin II Receptor Antagonist<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"924382-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924382-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"924382-s-7","title":"Mechanism Of Action","mono":"Systemic: Irbesartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptor . In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II . Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium . Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle . Irbesartan, by blocking the binding of angiotensin II to the AT 1 receptor, promotes vasodilation and decreases the effects of aldosterone . The negative feedback regulation of angiotensin II on renin secretion also is inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure-lowering effect that occurs .<br\/>"},"8":{"id":"924382-s-8","title":"Pharmacokinetics","sub":[{"id":"924382-s-8-23","title":"Absorption","mono":"<ul><li>Systemic: Rapidly absorbed .<\/li><li>Bioavailability: 60 to 80%; food effects none<\/li><\/ul>"},{"id":"924382-s-8-24","title":"Distribution","mono":"Systemic: Vd: 53 to 93 L  <br\/>"},{"id":"924382-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic: via CYP2C9 pathway     <br\/>"},{"id":"924382-s-8-26","title":"Excretion","mono":"Systemic: Fecal: 80%; Renal: 20%<br\/>"},{"id":"924382-s-8-27","title":"Elimination Half Life","mono":"Systemic:  11 to 15 hr  <br\/>"}]},"9":{"id":"924382-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>take with or without food <br\/>"},"10":{"id":"924382-s-10","title":"Monitoring","mono":"<ul><li>blood pressure, heart rate<\/li><li>renal function, electrolyte panel (eg; potassium, sodium)<\/li><\/ul>"},"11":{"id":"924382-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 75 MG, 150 MG, 300 MG<br\/><\/li><li><b>Avapro<\/b><br\/>Oral Tablet: 75 MG, 150 MG, 300 MG<br\/><\/li><\/ul>"},"13":{"id":"924382-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause diarrhea, heartburn, headache, upper respiratory infection, fatigue, or angioedema (deep swelling around eyes and lips and sometimes hands and feet).<\/li><li>Advise patient against sudden discontinuation of drug.<\/li><\/ul>"}}}